Charles J. Casamento Acquires 13,000 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Stock

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Director Charles J. Casamento purchased 13,000 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was purchased at an average cost of $2.56 per share, for a total transaction of $33,280.00. Following the transaction, the director now owns 13,000 shares of the company’s stock, valued at $33,280. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Relmada Therapeutics Stock Up 8.3 %

Shares of NASDAQ RLMD opened at $3.27 on Friday. Relmada Therapeutics, Inc. has a 12 month low of $1.88 and a 12 month high of $7.22. The business’s 50 day moving average is $3.21 and its two-hundred day moving average is $3.79.

Relmada Therapeutics (NASDAQ:RLMD) last released its earnings results on Wednesday, August 7th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.24. During the same quarter last year, the firm earned ($0.84) EPS. On average, equities research analysts expect that Relmada Therapeutics, Inc. will post -2.39 EPS for the current year.

Analyst Ratings Changes

Separately, The Goldman Sachs Group lowered shares of Relmada Therapeutics from a “neutral” rating to a “sell” rating and cut their target price for the stock from $3.00 to $2.00 in a research report on Wednesday, June 5th.

Hedge Funds Weigh In On Relmada Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in shares of Relmada Therapeutics during the first quarter valued at approximately $53,000. State Board of Administration of Florida Retirement System acquired a new stake in Relmada Therapeutics during the first quarter worth $70,000. American Century Companies Inc. increased its holdings in Relmada Therapeutics by 14.6% in the 2nd quarter. American Century Companies Inc. now owns 31,618 shares of the company’s stock valued at $95,000 after buying an additional 4,027 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of Relmada Therapeutics in the 4th quarter valued at $243,000. Finally, Renaissance Technologies LLC raised its stake in shares of Relmada Therapeutics by 153.6% in the 2nd quarter. Renaissance Technologies LLC now owns 88,775 shares of the company’s stock valued at $266,000 after buying an additional 53,767 shares in the last quarter. 45.24% of the stock is currently owned by institutional investors.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.